Pinnbrook Capital Management LP Increases Stock Position in Natera, Inc. $NTRA

Pinnbrook Capital Management LP lifted its holdings in Natera, Inc. (NASDAQ:NTRA) by 16.6% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 41,882 shares of the medical research company’s stock after purchasing an additional 5,968 shares during the period. Natera comprises 1.3% of Pinnbrook Capital Management LP’s holdings, making the stock its 22nd biggest position. Pinnbrook Capital Management LP’s holdings in Natera were worth $9,595,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of NTRA. JPMorgan Chase & Co. lifted its position in shares of Natera by 9.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock worth $1,871,914,000 after purchasing an additional 1,003,129 shares during the period. Franklin Resources Inc. lifted its position in shares of Natera by 37.5% in the 3rd quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock worth $428,987,000 after purchasing an additional 727,366 shares during the period. AQR Capital Management LLC lifted its position in shares of Natera by 39.0% in the 3rd quarter. AQR Capital Management LLC now owns 2,400,065 shares of the medical research company’s stock worth $386,338,000 after purchasing an additional 673,315 shares during the period. Millennium Management LLC lifted its position in shares of Natera by 215.7% in the 3rd quarter. Millennium Management LLC now owns 527,942 shares of the medical research company’s stock worth $84,983,000 after purchasing an additional 360,733 shares during the period. Finally, Robeco Institutional Asset Management B.V. lifted its position in shares of Natera by 5,965.1% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 343,768 shares of the medical research company’s stock worth $78,754,000 after purchasing an additional 338,100 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

NTRA has been the subject of several research reports. Morgan Stanley lowered their price target on shares of Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research report on Tuesday, March 3rd. William Blair initiated coverage on shares of Natera in a research report on Tuesday, April 14th. They issued an “outperform” rating for the company. Wall Street Zen cut shares of Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Wells Fargo & Company upped their price target on shares of Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $256.60.

Insider Activity at Natera

In other Natera news, CEO Steven Leonard Chapman sold 902 shares of the firm’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $206.16, for a total value of $185,956.32. Following the completion of the transaction, the chief executive officer owned 149,867 shares of the company’s stock, valued at approximately $30,896,580.72. This trade represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 291 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $206.16, for a total transaction of $59,992.56. Following the completion of the transaction, the insider directly owned 187,220 shares of the company’s stock, valued at approximately $38,597,275.20. This represents a 0.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 38,266 shares of company stock valued at $7,747,808 over the last 90 days. Company insiders own 5.63% of the company’s stock.

Natera Stock Performance

Natera stock opened at $203.69 on Friday. The stock has a market cap of $29.17 billion, a PE ratio of -124.96 and a beta of 1.57. The stock has a 50-day moving average of $200.78 and a two-hundred day moving average of $215.41. Natera, Inc. has a one year low of $131.81 and a one year high of $256.36.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.81. Natera had a negative return on equity of 14.74% and a negative net margin of 9.05%.The business had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. During the same quarter in the previous year, the firm earned ($0.41) earnings per share. As a group, sell-side analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.